Digital medtech company Endotronix Inc reported on Friday the completion of USD45m under its Series D financing round lead by investors.

The round was led by LSP, investing from its LSP Health Economics Fund 2, and included Aperture Venture Partners, BioVentures Investors, Lumira Ventures, OSF Ventures, Seroba Life Sciences, SV Health Investors, Wanxiang Healthcare Investments as well as an unnamed corporate strategic investor.

Under the terms of the financing, Endotronix will expand the board of directors to include Fouad Azzam PhD, General Partner at LSP.

According to Endotronix, the financing will be used to support the commercialisation of the Cordella Heart Failure System (Cordella System) and clinical development of the Cordella Pulmonary Artery Sensor (Cordella Sensor) through CE Marking and FDA Premarket Approval (PMA). The Cordella System is a proactive heart failure solution that brings patient management into the digital age and allows physicians to treat more patients with guideline-based therapy. The easy-to-use system extends clinical care into the home by collecting and securely transmitting daily patient data and insights to the heart failure clinician to guide therapy and optimal dosing.